Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Blood|September 16, 2006
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsPhilippe Rousselot, Francoise Huguet, Delphine Rea, et al.Blood|December 29, 2006
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaStephane Picard, Karine Titier, Gabriel Etienne, et al.Carcinogenesis|August 2, 2002
Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cellsHélène Ferry-Dumazet, Olivier Garnier, Maria Mamani-Matsuda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Prognostic significance of copy-number alterations in multiple myelomaHervé Avet-Loiseau, Cheng Li, Florence Magrangeas, et al.British Journal of Haematology|April 22, 2005
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remissionEric Jourdan, Françoise Rigal-Huguet, Gerald Marit, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 TrialsJean-Luc Harousseau, Herve Avet-Loiseau, Michel Attal, et al.Blood|January 7, 2006
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myelomaFrederic Garban, Michel Attal, Mauricette Michallet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJean-Luc Harousseau, Michel Attal, Hervé Avet-Loiseau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.Blood|July 29, 2006
Maintenance therapy with thalidomide improves survival in patients with multiple myelomaMichel Attal, Jean-Luc Harousseau, Serge Leyvraz, et al.Pageof 4